Patients with dry age-related macular degeneration experienced improvements in best corrected visual acuity after treatment with risuteganib, according to a phase 2a study.
Study author David S. Boyer, MD, told Healio/OSN that unmet needs remain in the treatment of dry AMD.
“The treatment of neovascular age-related macular degeneration has undergone a renaissance in the last 2 decades,” he said. “Unfortunately, there remains a lack of treatment for dry macular degeneration, though numerous trials are investigating the treatment of patients with dry macular degeneration